SecBot SecBot
424B5 ·Filed Jun 16, 2026

PHGE

BiomX Inc.
BEARISH
Impact 5/10
Horizonweeks Processed5mo ago SEC0001213900-26-069312
Notable filing: 424B5
Actionable Insight ▼ Bearish

The replenished ATM capacity ($5.06M) is a material dilutive risk for a $6M market cap stock. Expect continuous downward pressure as Wainwright sells into the market. Combined with the separate S-3 resale registration covering up to 5.3M shares from pre-funded warrants and convertible preferred, the total potential share overhang is severe. Short-term bearish; avoid longs until ATM activity is exhausted and share count stabilizes.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.5500
T+0 close · Jun 16, 2026 · via day close
Latest settled
+236.36%
T+60 · $1.85
Vs SPY
+233.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $0.5500entry
  2. T+1 · 5mo ago −5.47%α −6.25% · $0.5199
  3. T+5 · 5mo ago −24.27%α −23.23% · $0.4165
  4. T+20 · 4mo ago −62.36%α −63.68% · $0.2070
  5. T+60 · 2mo ago +236.36%α +233.22% · $1.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX filed a prospectus supplement to update its ATM offering capacity, authorizing up to $5,061,000 in common stock sales through H.C. Wainwright. This updates prior ATM programs under the same S-3 shelf. The filing is a routine administrative update to replenish offering capacity under the shelf's I.B.6 limitations and does not represent a new primary offering. Given the micro-cap ($6M market cap) and the dilutive overhang, the incremental capacity is notable for the stock's float.

Key Facts

  • Up to $5,061,000 of common stock may be sold via ATM through H.C. Wainwright (replaces prior ATM capacity).
  • Previously sold $1,376,214 under prior supplements on the same S-3 shelf.
  • Outstanding shares: 11,797,449 as of June 16, 2026. Stock closed at $0.555/shr on June 15, 2026.
  • Market cap ~$6M; the new ATM capacity represents ~84% of current market cap (at $0.555/shr).
  • Non-affiliate public float valued at $19.25M based on $1.84 reference price from April 17, 2026.
  • 12-month prior I.B.6 sales total $1,355,841. New limit of $5,061,000 resets the available capacity.
  • The shelf also covers a separate resale registration (S-3 filed Feb 2026) for up to 5,310,933 shares from convertible preferred and warrants, creating additional potential dilution.

Financial Impact

Up to $5,061,000 in new ATM capacity, equivalent to roughly 84% of current market cap at the June 15 closing price of $0.555/shr. Overhang is significant for a micro-cap issuer.

dilutionmarketCapshareCount

Risk Factors

  • Massive potential dilution relative to current float, $5.06M ATM plus 5.3M additional shares from the S-3 resale registration.
  • ATM at-the-market sales by H.C. Wainwright likely to pressure price near the $0.555 level or lower.
  • Micro-cap with weak institutional base (top holder Morgan Stanley at ~$72K) has limited absorption capacity.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001213900-26-069312
Document: 0001213900-26-069312-index-headers.html0001213900-26-069312
Document: 0001213900-26-069312-index.html0001213900-26-069312
Document: 0001213900-26-069312.txt0001213900-26-069312

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026